Bristol Myers Squibb disclosed that its drug stavartanate did not successfully i...
Merck & Co. is taking a significant step toward transforming its peptide therapi...
Sanofi’s ambition to become a dominant force in immunology continues to take sha...
Eli Lilly’s oral GLP-1 receptor agonist orforglipron has met its primary efficac...
GSK has received regulatory approval in the United Kingdom for two new combinati...
The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vac...
The executive order aims to lower prescription prices, but targets the mechanism...
Glycomine’s Series C raise highlights investor confidence in the company amid pr...
The agreement is seen as a win for global health ahead of the US withdrawal from...
Our editorial team dissects the latest developments in the ongoing story of how ...
Lilly plans to submit orforglipron for approval in weight management by the end ...
The FDA has accepted Regeneron Pharmaceuticals’ sBLA for Eylea HD (aflibercept) ...
Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid fail...
Leveraging Trump’s impending tariffs, pharma companies have called on Europe aga...
The US Food and Drug Administration (FDA) has granted approval for Neurelis’ dia...
University of Utah Health researcher Wesley Sundquist, PhD, has recently gained ...
